dc.contributor | Universidade Estadual Paulista (Unesp) | |
dc.contributor | Universidade de São Paulo (USP) | |
dc.contributor | University of San Diego | |
dc.date.accessioned | 2019-10-06T15:36:33Z | |
dc.date.accessioned | 2022-12-19T18:31:09Z | |
dc.date.available | 2019-10-06T15:36:33Z | |
dc.date.available | 2022-12-19T18:31:09Z | |
dc.date.created | 2019-10-06T15:36:33Z | |
dc.date.issued | 2019-03-01 | |
dc.identifier | Peritoneal Dialysis International, v. 39, n. 2, p. 183-187, 2019. | |
dc.identifier | 1718-4304 | |
dc.identifier | 0896-8608 | |
dc.identifier | http://hdl.handle.net/11449/187453 | |
dc.identifier | 10.3747/pdi.2018.00092 | |
dc.identifier | 2-s2.0-85062832421 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5368491 | |
dc.description.abstract | Studies on vancomycin pharmacokinetics in acute kidney injury (AKI) patients on high-volume peritoneal dialysis (HVPD) are lacking. We studied the pharmacokinetics of intravenous (IV) vancomycin in AKI patients treated by HVPD who received a prescribed single IV dose of vancomycin (15 – 20 mg/kg total body weight) to determine the extent of vancomycin removal and to establish vancomycin dosing guidelines for the empirical treatment of AKI patients receiving HVPD. The application of 18 mg/kg vancomycin every 48 – 72 hours in AKI patients undergoing HVPD was required to maintain therapeutic concentrations. | |
dc.language | eng | |
dc.relation | Peritoneal Dialysis International | |
dc.rights | Acesso restrito | |
dc.source | Scopus | |
dc.subject | AKI | |
dc.subject | sepsis | |
dc.title | Vancomycin removal during high-volume peritoneal dialysis in acute kidney injury patients | |
dc.type | Artículos de revistas | |